Patrick K. Reville

Also affiliated with The University of Texas MD Anderson Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 19 papers. Top paper: “Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial”.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Nature Communications(2021)10.1038/s41467-021-26282-z

N/A

0.734DataRank · unranked

132 citations

Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin S. Im, Patrick K. Reville +28 more

Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Nature Communications(2024)10.1038/s41467-024-45916-6

N/A

0.631DataRank · unranked

66 citations

Patrick K. Reville, Mhd Yousuf Yassouf, Fatima Zahra Jelloul, Christopher Ly, Poonam N. Desai +27 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0.483DataRank · unranked

24 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Blood(2025)10.1182/blood.2024027244

N/A

0.465DataRank · unranked

13 citations

Bofei Wang, Jennifer Marvin‐Peek, Bin Yuan, Yu-Jen Kuo, Araceli Isabella Garza +17 more

Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)

Blood Cancer Journal(2024)10.1038/s41408-024-00981-4

N/A

0.287DataRank · unranked

4 citations

Warren Fiskus, Courtney D. DiNardo, Patrick K. Reville, John A. Davis, Christine Birdwell +10 more

Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008318

N/A

0DataRank · unranked

8 citations

Gopi S. Mohan, Bofei Wang, Tianhao Li, Naval Daver, Yuting Zhao +4 more

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood(2024)10.1182/blood-2024-203706

N/A

0DataRank · unranked

5 citations

Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia +21 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction

Current Opinion in Pharmacology(2025)10.1016/j.coph.2025.102526

N/A

0DataRank · unranked

14 citations

Patrick K. Reville, Hussein A. Abbas, Bofei Wang

Multimodal spatial proteomic profiling in acute myeloid leukemia

npj Precision Oncology(2025)10.1038/s41698-025-00897-7

N/A

0DataRank · unranked

10 citations

Ivo Veletić, Christopher D. Pacheco, Enes Dasdemir, Fatima Zahra Jelloul, Sammy Ferri‐Borgogno +15 more

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry

Blood Immunology & Cellular Therapy(2025)10.1016/j.bict.2025.100004

N/A

0DataRank · unranked

4 citations

Jessica L. Root, Poonam N. Desai, Nicole Vaughn, Ferdinandos Skoulidis, Hussein A. Abbas +2 more

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.03.278309

N/A

0DataRank · unranked

3 citations

Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin S. Im, Patrick K. Reville +22 more

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations

Blood Cancer Journal(2025)10.1038/s41408-025-01251-7

N/A

0DataRank · unranked

1 citations

Christopher P. Mill, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan +18 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

0DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Maintenance Therapy in AML

Frontiers in Oncology(2021)10.3389/fonc.2020.619085

N/A

0DataRank · unranked

32 citations

Tapan M. Kadia, Patrick K. Reville

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

Frontiers in Immunology(2021)10.3389/fimmu.2021.659625

N/A

0DataRank · unranked

17 citations

Patrick K. Reville, Xianli Jiang, Hui Yang, Alexandre Reuben, Jin S. Im +6 more

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood(2024)10.1182/blood.2023022832

N/A

0DataRank · unranked

42 citations

Jessica Piel, Michael P. Collins, Murphy Hentemann, Branko Cuglievan, Christopher P. Mill +21 more

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions

Cancer Cell(2024)10.1016/j.ccell.2024.02.011

N/A

0DataRank · unranked

31 citations

Priya Lakra, Panhong Gou, Haopeng Yang, Cem Meydan, Matthew Teater +24 more